Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2007;38:e60
Published online before print May 24, 2007, doi: 10.1161/STROKEAHA.107.483529
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/7/e60    most recent
STROKEAHA.107.483529v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pérez-Díaz, H.
Right arrow Articles by Gil-Peralta, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pérez-Díaz, H.
Right arrow Articles by Gil-Peralta, A.

(Stroke. 2007;38:e60.)
© 2007 American Heart Association, Inc.


Letters to the Editor

Intravenous Thrombolysis for Acute Ischemic Stroke After Vitrectomy for Retinal Detachment

Hernando Pérez-Díaz, MD; Manuel Carballo, MD, PhD Alberto Gil-Peralta, MD, PhD

Department of Neurology, Hospitales Universitarios Virgen del Rocío, Sevilla, Spain

To the Editor:

Once the benefits of intravenous tissue plasminogen activator (tPA) in the treatment of acute ischemic stroke have been proved, it should be interesting to widen its use. We discuss the fact that intravenous thrombolysis with tPA may not be a contraindication to treat an acute ischemic stroke occurring soon after surgical repair of retinal detachment (RD) by means of vitrectomy.

A 65-year-old woman with a history of atrial fibrillation underwent vitrectomy for surgical repair of RD in her right eye. Vitrectomy required 3 incisions into the posterior chamber of the eye using a vitreous cutter of 25 G, an infuser of 20 G, and a light source of 20 G. Thirty-two hours later, and while in the hospital, she experienced an embolic ischemic stroke in the left middle cerebral artery territory. Immediately after the stroke onset, the NIHSS was 13. Despite the recent surgical procedure and considering the degree of neurological deficit, we decided a tPA intravenous thrombolysis according to the SITS-MOST protocol. Both the tolerance and response of the patient were satisfactory and her NIHSS score at completion of tPA intravenous thrombolysis was 0. No complications were observed.

Vitrectomy is the most common surgical procedure used to repair RD, combined, in most cases, with scleral buckling. In this procedure the vitreous is removed and replaced with saline solution, intraocular gas, or silicone oil to repair the retinal defect. Suprachoroidal hemorrhage (SCH), which usually causes secondary acute glaucoma, is a serious but exceptional complication. Most commonly, a vitreous hemorrhage (VH) may occur affecting visual prognosis depending on its severity. No prospective studies analyzing the incidence of both complications in relation to the surgical repair of RD have been reported. Falkner et al1 reported a 4.3% VH incidence in a large retrospective sample of patients undergoing vitrectomy, whereas Sharma et al2 observed a 0.17% incidence of SCH in another retrospective sample. Risk factors associated with the occurrence of SCH during vitrectomy include old age, severe myopia, history of surgical repair of RD, rhegmatogenous RD, the use of cryotherapy, intraoperative systemic hypertension, and, as a technical factor, scleral buckling combined with vitrectomy.3,4

Regarding the use of thrombolytic therapy, 3 cases of spontaneous SCH secondary to the systemic administration of intravenous tPA for acute myocardial infarction5–7 have been reported. There are, however, no reports of secondary VH.

The only formal contraindication for the administration of intravenous tPA in our patient would have been the recent puncture at a noncompressible site, which might cause VH. In this sense, we must remark that the instruments used in the surgical procedure were not thick, ranging from 20 to 25 G, and that their risk of causing VH seemed low according to the evidence found in the literature. However, it is well-known that VH and SCH occur immediately after surgery, that the risk decreases with time, and that the development of severe glaucoma is a sign of hemorrhage. In our patient these complications went unnoticed; 32 hours had elapsed from surgery, she presented a severe stroke, and the therapeutic window was very short, so after balancing risks and benefits we decided to treat her with intravenous tPA. Fortunately, the clinical result was excellent and the patient recovered completely at the completion of the treatment.

In view of this, in our opinion surgical repair of RD by means of vitrectomy in combination or not with scleral buckling does not pose an absolute contraindication for the administration of intravenous tPA for acute ischemic cerebral stroke.

Acknowledgments

Disclosures

None.

References

  1. Falkner C, Binder S, Kruger A. Outcome after silicone oil removal. Br J Ophthalmol. 2001; 85: 1324–1327.[Abstract/Free Full Text]
  2. Sharma T, Virdi DS, Parikh S, Gopal L, Badrinath SS, Mukesh BN. A case control study of suprachoroidal hemorrhage during pars plana vitrectomy. Ophthalmic Surg Lasers. 1997; 28: 640–644.[Medline] [Order article via Infotrieve]
  3. Tabandeh H, Flynn HW. Suprachoroidal hemorrhage during pars plana vitrectomy. Curr Opin Ophthalmol. 2001; 12: 179–185.[CrossRef][Medline] [Order article via Infotrieve]
  4. Wickham L, Connor M, Aylward GW. Vitrectomy and gas for inferior break retinal detachments: are the results comparable to vitrectomy, gas, and scleral buckle? Br J Ophthalmol. 2004; 88: 1376–1379.[Abstract/Free Full Text]
  5. Asensio VM, Pérez FJ, Carlos J, Merino F. Suprachoroidal haemorrhage and acute glaucoma associated wit systemic fibrinolysis. Arch Soc Esp Oftalmol. 2002; 77: 459–462.[Medline] [Order article via Infotrieve]
  6. Chorich LJ, Derick RJ, Chambers RB, Cahill KV, Quartetti EJ, Fry JA, Bush CA. Hemorrhagic ocular complications associated with the use of systemic thrombolytic agents. Ophthalmology. 1998; 105: 428–431.[CrossRef][Medline] [Order article via Infotrieve]
  7. Khawly JA, Ferrone PJ, Holck DE. Choroidal hemorrhage associated with systemic tissue plasminogen activator. Am J Ophthalmol. 1996; 121: 577–578.[Medline] [Order article via Infotrieve]




This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/7/e60    most recent
STROKEAHA.107.483529v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pérez-Díaz, H.
Right arrow Articles by Gil-Peralta, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pérez-Díaz, H.
Right arrow Articles by Gil-Peralta, A.